Compare FTLF & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | PEPG |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 121.7M |
| IPO Year | 2006 | 2022 |
| Metric | FTLF | PEPG |
|---|---|---|
| Price | $10.04 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.50 | $11.17 |
| AVG Volume (30 Days) | 27.6K | ★ 883.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $21,744,000.00 | N/A |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $60.76 | ★ N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $8.67 | $1.01 |
| 52 Week High | $20.98 | $7.80 |
| Indicator | FTLF | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 35.85 |
| Support Level | $8.79 | $1.32 |
| Resistance Level | $15.34 | $5.37 |
| Average True Range (ATR) | 0.83 | 0.15 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 45.88 | 24.11 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.